Sayed Yossef, MD
Gastroenterology · Poland, OHNPI 1487657219
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $40,850 of the $55,241 with a category attached, or 73.9%. 35 manufacturers reported payments, led by Phathom Pharmaceuticals, Inc. at 47.8% of the total. Reporting peaked in 2024 at $20,912 and has fallen 67.1% since, to $6,882 in 2025. Among gastroenterology clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 596 payments — averaging $92.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Phathom Pharmaceuticals, Inc.$26K
- AbbVie$21K
- Romark Laboratories, LC$1K
- Boston Scientific$945
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$940
- Takeda Pharmaceuticals U.S.A., Inc.$731
- plus $4K from 29 others
Across 88 payments — averaging $10,168 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$766K
- Janssen Research & Development, LLC$49K
- AstraZeneca$23K
- Ferring Pharmaceuticals AS$19K
- Sanofi US Services Inc.$17K
- Pfizer$16K
- plus $5K from 1 others
What the payments were for
- Consulting fees$1,0002%
- Speaking & faculty fees$40,85074%
- Travel & lodging$2,2674%
- Food & beverage$10,97820%
- Education$1460%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Phathom Pharmaceuticals, Inc. | 65 | $26,400 |
| AbbVie(2 entities) | 227 | $21,500 |
| Romark Laboratories, LC | 9 | $1,141 |
| Boston Scientific | 11 | $945 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 62 | $940 |
| Takeda Pharmaceuticals U.S.A., Inc. | 38 | $731 |
| Johnson & Johnson(2 entities) | 31 | $603 |
| Ironwood Pharmaceuticals, Inc | 16 | $497 |
| Bristol Myers Squibb | 31 | $347 |
| Ardelyx, Inc. | 11 | $217 |
| Gilead | 11 | $185 |
| QOL Medical, LLC | 11 | $174 |
| Regeneron Healthcare Solutions, Inc. | 7 | $143 |
| E.r. Squibb & Sons, L.L.C. | 1 | $125 |
| Sanofi | 5 | $120 |
| Cook Medical LLC | 1 | $117 |
| Intercept Pharmaceuticals, Inc. | 7 | $114 |
| Pfizer | 6 | $114 |
| Amgen | 5 | $106 |
| Novo Nordisk | 1 | $105 |
| Merck | 5 | $89 |
| Nestle Healthcare Nutrition Inc. | 4 | $79 |
| Ferring Pharmaceuticals Inc. | 5 | $75 |
| Redhill Biopharma Inc. | 4 | $60 |
| Vivus LLC | 6 | $56 |
| Daiichi Sankyo Inc. | 2 | $37 |
| UCB, Inc. | 2 | $36 |
| Shionogi Inc | 2 | $32 |
| Boehringer Ingelheim | 2 | $31 |
| Eisai Inc. | 2 | $27 |
| Evoke Pharma, Inc. | 2 | $25 |
| Madrigal Pharmaceuticals | 1 | $22 |
| Concordia Pharmaceuticals Inc. | 1 | $19 |
| Conmed Corporation | 1 | $15 |
| Dova Pharmaceuticals | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VOQUEZNA$25,451
- LINZESS$16,899
- VIBERZI$7,237
- Alinia$3,000
- EXALT Model D$284
- ORISE$118
- EchoTip$117
- Wegovy$105
- EXALT MODEL D CONTROLLER$103
How this compares
$55,241 in reported general payments places this provider in the 90th percentile of 657 gastroenterology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 41 | $316,527 |
| StelaraUstekinumab | 12 | $307,846 |
| Humira PenAdalimumab | 14 | $191,426 |
| CreonLipase/Protease/Amylase | 43 | $148,051 |
| XifaxanRifaximin | 30 | $98,592 |
| Cimzia (2 Pack)Certolizumab Pegol | 12 | $67,159 |
| ZenpepLipase/Protease/Amylase | 16 | $63,002 |
| LinzessLinaclotide | 74 | $54,038 |
| MotegrityPrucalopride Succinate | 54 | $33,453 |
| VoqueznaVonoprazan Fumarate | 46 | $29,355 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 123 | $21,175 |
| Mesalamine | 38 | $19,597 |
| TrulancePlecanatide | 20 | $10,793 |
| MovantikNaloxegol Oxalate | 17 | $7,402 |
| Pantoprazole Sodium | 887 | $7,267 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $603 | $307,84612 claims |
| AbbVieCreon, Linzess | $21,500 | $202,089117 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $940 | $109,38550 claims |
| UCB, Inc.Cimzia (2 Pack) | $36 | $67,15912 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $731 | $33,45354 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $26,400 | $29,35546 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $75 | $21,175123 claims |
| Redhill Biopharma Inc.Movantik | $60 | $7,40217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 657 gastroenterology providers in Ohio.
Other gastroenterology in Poland
- Naim AlkhouriWestlake$1.9M
- Pierre GholamCleveland$1.6M
- Anita AfzaliCincinnati$798K
- Mohamed NaemWestlake$708K
- Kara de FeliceCincinnati$427K
- Tasos ManokasColumbus$411K
- Florian RiederCleveland$396K
- Allan PeckCincinnati$391K
- Dany RaadHighland Hills$387K
- Stanley CohenCleveland$338K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.